{"entity":{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","aka":[],"tldr":"A phase 3 trial of Olaparib, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) is a phase 3 interventional study registered as NCT05171816 by AstraZeneca, with 110 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2024-01-22. Interventions recorded: olaparib, abiraterone acetate. Conditions listed: Metastatic Castration-resistant Prostate Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05171816","url":"https://clinicaltrials.gov/study/NCT05171816"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib","abiraterone"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05171816","phase":"3","setting":"A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)","sponsor":"AstraZeneca","started":"2021-06-24","startedType":"actual","yearReported":2025,"enrolled":110,"enrolledBasis":"registry","outcomes":[{"endpoint":"Radiological Progression Free Survival (rPFS)","primary":true,"unit":"months","arms":[{"name":"Olaparib 300 mg bd + Abiraterone 1000 mg qd","n":54,"value":14.75,"note":"95% CI 12.06 to 22.11; Figures from the ClinicalTrials.gov results section (first posted 2025-06-29), not from a publication"},{"name":"Placebo bd + Abiraterone 1000 mg qd","n":56,"note":"NA - Not calculated, estimates cannot be calculated due to too few events"}],"hr":1.43,"ci":[0.83,2.48],"p":"0.2592","source":"https://clinicaltrials.gov/study/NCT05171816?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Olaparib 300 mg bd + Abiraterone 1000 mg qd","n":54,"value":27.83,"note":"95% CI 27.83 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-06-29), not from a publication"},{"name":"Placebo bd + Abiraterone 1000 mg qd","n":56,"note":"NA - Not calculated, estimates cannot be calculated due to too few events"}],"hr":1.14,"ci":[0.57,2.29],"p":"0.7251","source":"https://clinicaltrials.gov/study/NCT05171816?tab=results"}]},"route":"/trials/nct05171816/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"idea":[{"id":"idea-cost-low-dose-abiraterone-food","kind":"idea","name":"Prescribe a quarter dose of abiraterone with breakfast","route":"/ideas/idea-cost-low-dose-abiraterone-food/"}]}}